Approval will broaden the NARCAN® Nasal Spray portfolio, and improve cost-effectiveness by increasing flexibility and distribution efficiency of this life-saving medication GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for new multipack configurations of over-the-counter (OTC) NARCAN® Nasal Spray. This approval expands the NARCAN® Nasal Spray p ...

Core Viewpoint - Emergent BioSolutions Inc. will host a conference call on February 26, 2026, to discuss its financial results for Q4 and the full year of 2025 [1]. Group 1: Conference Call Details - The conference call will take place at 5:00 pm eastern time [1]. - Participants can access the call live via webcast or by visiting the Investors page of Emergent's website [2]. - Telephone participants must register in advance to receive a confirmation email with the dial-in number, unique passcode, and registrant ID [2]. Group 2: Replay Information - A replay of the conference call will be available on the Investors page of Emergent's website [3]. Group 3: Company Overview - Emergent BioSolutions has been dedicated to protecting public health for over 25 years, providing life-saving solutions for various health threats [4]. - The company addresses health challenges such as smallpox, mpox, botulism, Ebola, anthrax, and opioid overdose emergencies [4]. - Emergent encourages engagement through its website and social media platforms [4]. Group 4: Contact Information - Investor contact is Richard S. Lindahl, Executive Vice President and CFO [5]. - Media contact is Assal Hellmer, Vice President of Communications [5].

Group 1 - Melissa Seymour has been appointed as the new Chair of the Parenteral Drug Association (PDA), succeeding Anil Sawant, who served in this role for the past two years [1] - Ken Paddock and Jackie Veivia-Panter have joined the PDA board following the fall elections [1] - The board members completing their terms at the end of 2025 include Sue Schniepp (Immediate Past Chair) and Ivy Louis (Board Member) [1] Group 2 - The PDA is a leading global provider of science, technology, and regulatory information, focused on advancing pharma manufacturing science and regulation since its founding in 1946 [3] - The PDA aims to create awareness and understanding of important issues facing the pharmaceutical community and provides high-quality education relevant to the industry [3]

Group 1 - Emergent BioSolutions Inc. received an order worth up to $21.5 million from the US Department of War for the supply of BioThrax, the only FDA-approved anthrax vaccine [1][2] - Deliveries of BioThrax are expected to occur throughout 2026, with a one-year base period and optional extensions into 2027 and 2028, highlighting the company's ongoing role in US defense against biological threats [2] - The company announced a collaboration with PANTHER to fund the "MpOx Study in Africa," which is testing potential treatments for Mpox, positioning the company in a high-demand area amid ongoing outbreaks [3] Group 2 - Emergent BioSolutions is focused on providing solutions to public health threats, including opioid overdoses, infectious diseases, and biological threats [4]

Group 1 - Letitia James has accused Robert Kramer of selling his shares in Emergent before revealing contamination issues related to the production of the Covid-19 vaccine [1]

Company Overview - Emergent is a 25-year-old company focused on protecting and saving lives [3] - The company has initiated a multiyear turnaround plan starting in 2024 [3] Presentation Details - The presentation includes a Q&A session for both in-person and online participants [1][2] - The CEO, Joe Papa, is leading the presentation and discussing the company's progress [3]

Emergent BioSolutions FY Conference Summary Company Overview - **Company Name**: Emergent BioSolutions (NYSE:EBS) - **Industry**: Biodefense and Opioid Overdose Treatment - **Established**: 25 years ago - **Mission**: Protect and save lives through biodefense products and opioid overdose treatments [3][4] Core Business Areas 1. **Biodefense Products**: - Portfolio includes 11 products targeting serious threats like smallpox, anthrax, botulism, and Ebola [4][11] - Collaborates with U.S. and global governments for vaccine and therapeutic development [4][12] 2. **Opioid Overdose Treatment**: - Market leader with Narcan for opioid overdose treatment [4][20] - Focus on increasing access to Narcan, aiming for widespread availability [21][22] Turnaround Plan - **Timeline**: Multi-year plan initiated in 2024 - **Phases**: 1. **Stabilization** (2024-2025): Streamlined operations, divested $150 million in assets, reduced operating expenses by $250 million, and improved Adjusted EBITDA from negative in 2023 to $183 million in 2024 [7][30] 2. **Turnaround** (2025-2026): Focus on growth investments, both organic and inorganic [9][10] 3. **Transformation** (2026 and beyond): Aim for a sustainable and profitable company [10][32] Financial Performance - **Debt Reduction**: Total debt reduced by $275 million since 2023, with net leverage down from 9.9 times to approximately 2 times [8][30] - **Revenue Trends**: Revenue decreased due to divestitures but Adjusted EBITDA margin improved from 19% in 2024 to 33% in 2025 [29][30] - **Future Guidance**: Projected Adjusted EBITDA for 2025 between $195-$210 million [7] Market Dynamics - **Geographic Diversification**: Revenue from outside the U.S. increased from 15% to 34% [19] - **Bipartisan Support**: Strong political backing for biodefense initiatives and opioid overdose solutions [15][16] Product Innovations - **Narcan Backpack Kit**: Recently approved by the FDA to enhance accessibility for potential users [22][23] - **Partnerships**: Collaborations with RocketVax for rapid vaccine development and Hikma for Kloxxado, a higher dose naloxone product [24][25] Pipeline and Future Opportunities - **Key Products**: Ebanga for Ebola, TEMBEXA for smallpox, and Raxibacumab for anthrax [26][28] - **Clinical Trials**: New trials for TEMBEXA in mpox treatment initiated [28] - **Growth Investments**: Focus on expanding international reach and developing new products [31][46] Challenges and Competitive Landscape - **Naloxone Market**: Anticipated mid-single-digit growth in overall naloxone unit volume, with Narcan expected to maintain market leadership [36][37] - **Funding Opportunities**: Potential $50 billion from opioid litigation settlements to support naloxone distribution [41] Conclusion - Emergent BioSolutions is on track with its turnaround plan, focusing on growth and innovation while maintaining a commitment to patient safety and quality [32][33]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Combating Public Health Threats for Communities Around the World Company Overview 44th Annual J.P. Morgan Healthcare Conference Joe Papa President and Chief Executive Officer January 14, 2026 1 1 Safe Harbor Statement/Trademarks This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements, other than statements of historical fact, including statements regarding the future performance of the Company or any of our ...

Core Insights - Emergent BioSolutions has received FDA approval for a new carrying case for its NARCAN® Nasal Spray, aimed at enhancing accessibility and encouraging individuals to carry the life-saving medication during opioid emergencies [1][3] Product Development - The new packaging for NARCAN® Nasal Spray includes two blister packs and a Quick Start Guide, designed to be compact, discreet, and durable [1] - The carrying case aims to integrate seamlessly into daily life, addressing the low carry rate of the medication, which is currently at only 10% among the general consumer population [3] Consumer Insights - A survey conducted by Emergent revealed that 74% of consumers prefer a discreet carrying case over standard packaging, with this preference rising to 81% among college students, a high-risk group for opioid misuse [2] Market Impact - Since its prescription launch in 2016, over 85 million doses of NARCAN® have been distributed across the U.S. and Canada, indicating significant market penetration and demand for opioid overdose reversal solutions [4]